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Abstract A simple approach that allows cost-effective
automated puriﬁcation of recombinant proteins in levels
sufﬁcient for functional characterization or structural
studies is described. Studies with four human stem cell
proteins, an engineered version of green ﬂuorescent pro-
tein, and other proteins are included. The method combines
an expression vector (pVP62K) that provides in vivo
cleavage of an initial fusion protein, a factorial designed
auto-induction medium that improves the performance of
small-scale production, and rapid, automated metal afﬁnity
puriﬁcation of His8-tagged proteins. For initial small-scale
production screening, single colony transformants were
grown overnight in 0.4 ml of auto-induction medium,
produced proteins were puriﬁed using the Promega Max-
well 16, and puriﬁcation results were analyzed by Caliper
LC90 capillary electrophoresis. The yield of puriﬁed
[U-
15N]-His8-Tcl-1 was 7.5 lg/ml of culture medium, of
puriﬁed [U-
15N]-His8-GFP was 68 lg/ml, and of puriﬁed
selenomethione-labeled AIA–GFP (His8 removed by
treatment with TEV protease) was 172 lg/ml. The yield
information obtained from a successful automated puriﬁ-
cation from 0.4 ml was used to inform the decision to
scale-up for a second meso-scale (10–50 ml) cell growth
and automated puriﬁcation.
1H–
15N NMR HSQC spectra of
His8-Tcl-1 and of His8-GFP prepared from 50 ml cultures
showed excellent chemical shift dispersion, consistent with
well folded states in solution suitable for structure deter-
mination. Moreover, AIA–GFP obtained by proteolytic
removal of the His8 tag was subjected to crystallization
screening, and yielded crystals under several conditions.
Single crystals were subsequently produced and optimized
by the hanging drop method. The structure was solved by
molecular replacement at a resolution of 1.7 A ˚.T h i s
approach provides an efﬁcient way to carry out several key
target screening steps that are essential for successful
operation of proteomics pipelines with eukaryotic proteins:
examination of total expression, determination of proteol-
ysis of fusion tags, quantiﬁcation of the yield of puriﬁed
protein, and suitability for structure determination.
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Introduction
The productivity of high-throughput structural genomics
endeavors is critically dependent on how efﬁciently the
best target proteins for structure determination can be
identiﬁed [1, 2]. This applies to natural proteins as well as
to products of engineering strategies, such as domain
subcloning [3–5], modiﬁcations of the N- and C-termini [6,
7], surface entropy reduction [8, 9], and chemical alkyl-
ation of lysines [10]. The pipeline used by most structural
genomic centers defers the evaluation of whether a target
protein is amenable for structure determination until after
the target protein has been successfully produced and
puriﬁed in quantities of tens of milligrams. This approach
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determine whether a protein is suitable for structure
determination, for example its stability, whether it is well-
folded in solution, and whether it can be crystallized, only
become apparent during
1H–
15N HSQC measurements [7,
11, 12] or crystallization screening [13–15], and this is
after considerable labor and resources have been expended.
Ideally, a bioinformatics evaluation would identify
proteins best suited for structure determination [16, 17], but
it is still difﬁcult to signiﬁcantly improve the output of
protein structures based on this approach alone [18, 19].
Consequently, experimental methods to identify the best
proteins are still required, and obtaining predictive results
as early in the production pipeline as possible and with
minimal labor and resources used has become a focus of
much effort [20–27].
The Center for Eukaryotic Structural Genomics (CESG)
has worked to develop simple, efﬁcient small-scale
screening methods that successfully predict the results of
large-scale protein puriﬁcation. In previous studies, we
have examined individual steps in the protein production
and structure determination process [28–31]. Recently, we
have begun to combine improvements in expression vector
engineering [32], in vivo fusion proteolysis of fusion pro-
teins [33], and factorial evolution of auto-induction
medium [33] with a bench top, automated method to pre-
pare highly puriﬁed proteins required for structural
evaluations. Here we show that this combination enables
rapid production of labeled proteins that can be used
directly in NMR and X-ray studies.
Materials and methods
Chemicals
Unless otherwise stated, bacterial growth reagents, antibi-
otics, routine laboratory chemicals, and disposable lab
supplies were from Sigma-Aldrich (St. Louis, MO), Fisher
(Pittsburgh PA) or other major distributors. L-Selenome-
thionine was from Acros (Morris Plains, NJ); [U-
15N]-
NH4Cl (98%) was from Cambridge Isotope Laboratories
(Andover, MA). Preparation of standard laboratory
reagents was as previously described [34]. Deep-well
growth blocks were from Qiagen (Valencia, CA). AeraSeal
gas permeable sealing tape (T-2421-50) was from ISC
Bioexpress (Kaysville, UT).
Plasmids
Genes were cloned into the expression vectors pVP56 and
pVP62 [32, 33] using the Flexi Vector system (Promega,
Madison WI). Vector pVP56 yields a TEV protease
cleavable His8-maltose binding protein (His-MBP) fused
to the N-terminus of the protein target. Vector pVP62
yields an MBP fusion that can undergo in vivo proteolysis
to liberate a His8-tagged target protein. Selection during
cloning was provided by substitution of the gene of interest
for the toxic insert of barnase and chloramphenicol ace-
tyltransferase bounded by the SgfI and PmeI restriction
sites. Plasmids containing the lethal barnase gene must be
propagated in a barnase-resistant strain (e.g., Escherichia
coli BR610, which is available through Technical Services,
Promega Corporation).
Expression vector for in vivo proteolysis
Figure 1 shows a map of the CESG expression vector
pVP62K. The vector produces an MBP-TVMV-His8-TEV-
target fusion, where MBP represents maltose binding pro-
tein, TVMV represents a tobacco vein mottling virus
protease recognition site, and where TEV represents a
tobacco etch virus protease recognition site. Genes are
cloned into the SgfI and PmeI restriction sites that bound
the Bar-CAT cassette. Self-ligation of the vector through
the SgfI and PmeI sites is reduced by the inclusion the 30
homology region [32], which is uniquely bounded by PmeI
and HindIII restriction sites. LacI is expressed from this
vector under control of the natural lac promoter [35]. The
vector reserves the AvrII and BsiWI restriction sites to
deﬁne an antibiotic resistance cassette so that the kana-
mycin resistance gene and promoter can be swapped with
other antibiotic resistance genes and promoters. The vector
also provides weak constitutive expression of TVMV
protease under control of the tet promoter [33]. The LacI,
kanamycin nucleotidyltransferase, and TVMV protease
coding regions all have a 30 transcriptional terminator to
inhibit read-through expression.
The pRARE2 plasmid for rare codon supplementation
was isolated from E. coli Rosetta2 cells (EMD Biosci-
ences/Novagen) using a Qiagen miniprep kit.
Primer design
The DNA (GCG, Madison, WI) and Lasergene (DNAStar,
Madison, WI) software were used to design and assemble
primers used for PCR and sequencing. Overlap extension
PCR [34] was used to synthesize a gene for green ﬂuo-
rescent protein (GFP) with E. coli codon optimization and
the F64L, S65T, R81Q, F99S, M153T, and V163A muta-
tions [36–38]. ‘‘One pot’’ recursive PCR was used to carry
out de novo synthesis of the GFP gene [39–41]. Ten
ssDNA primers with lengths of 90–95 bases (Table 1)
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123were designed based on the coding and non-coding DNA
strands so that *20 bases at their ends overlapped with the
adjacent primers and could be extended during the recur-
sive PCR cycles. The eight internal primers (2–9 in
Table 1) were used at a concentration of 0.25 pM, and each
of the ﬂanking primers (1, 10 in Table 1) were used at
50 pM. The recursive PCR conditions were as follows:
80C for 5 min; then 30 cycles of 94C for 45 s, 55C for
1 min, and 72C for 1 min; and a ﬁnal extension step of
72C for 20 min. PCR was performed using Deep Vent
DNA polymerase (New England Biolabs, Ipswich, MA) on
an MJ Research (Waltham, MA) Peltier Thermal Cycler.
The synthesized gene was puriﬁed using a Qiagen PCR
puriﬁcation kit (Valencia, CA), digested with NdeI (New
England BioLabs) and BamHI (Promega) restriction
enzymes, and ligated into similarly digested pET9a (EMD
Biosciences/Novagen, Madison, WI) using standard
molecular biology techniques [42]. The cloned GFP gene
was subsequently used as a template for PCR ampliﬁcation
to prepare the GFP gene for Flexi Vector cloning into
pVP62K [32, 33].
Bacterial expression strain
ThemethionineauxotrophE. coliB834(genotypeF
-ompT
hsdSB(rB
-mB
-) gal dcm met, [43, 44]) was transformed with
pRARE2 and used for either selenomethionine or
15N
labeling [28, 29].
Proteins investigated
Table 2 summarizes the proteins investigated in this work.
For some proteins, results from studies using a previously
described pipeline are included [29, 30].
Cell growth, protein production, and cell lysis
The methods for bacterial growth, protein production, and
analysis were described elsewhere [28–30]. For the
15N
labeling in the auto-induction medium [28],
15N Celtone
liquid (Spectra Stable Isotopes, Columbia, MD) was added
(5% v/v) to stimulate protein expression.
Target genes were screened for production at the
small-scale (0.4 ml) in 96-well growth blocks using an
auto-induction medium modiﬁed from the original [45]t o
better match correlation between small- and large-scale
production [33]. Meso-scale cell cultures (10–50 ml) for
structural studies were grown as replicates in the 96-well
growth blocks or in 0.5 l bafﬂed shaking ﬂasks (50 ml of
medium per ﬂask). Cells were grown for 24 h at 25C
with shaking at *250 rpm on a microplate shaker (VWR,
Fig. 1 Expression vector pVP62K. (a) Linear map showing key
features of the vector and location of the Bar-CAT toxic cassette and
30 homology region (30-hmr) for Flexi Vector cloning. (b) Nucleotide
and encoded protein sequence in the linker region near to the SgfI
cloning site. The TVMV protease site is ETVRFQS, where proteol-
ysis occurs between the Q and S residues. The fusion protein may be
cleaved in the expression host due to the presence of a low level of
TVMV protease produced by constitutive expression from pVP62K.
The TEV protease site is ENLYFQA, where proteolysis occurs
between the Q and A residues. After puriﬁcation of the His8-tagged
protein, the His8 tag can be removed by treatment with TEV protease
to release an N-terminal AIA-target
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123West Chester, PA). After completion of the auto-induction
protocol, bacterial cell cultures were harvested by centri-
fugation at 4,000 rpm and 4C for 10–15 min using either
an Allegra 6R centrifuge with a GH3.8 rotor or an Avanti
J30-I with a JS5.9 rotor (Beckman Coulter, Fullerton, CA).
The pelleted cells were suspended in 8 ml of lysis buffer
containing 50 mM NaH2PO4, pH 7.4, 0.5 M NaCl, 20%
(w/v) ethylene glycol, and 1 mg/ml lysozyme (EMD Bio-
sciences/Novagen). Protease inhibitors (E-64, 1.0 lM,
Sigma, St. Louis, MO; benzamidine, 0.5 mM, Calbiochem,
La Jolla, CA) were added to the cell suspension. A second
lysis buffer was used for meso-scale (50 ml) protein pro-
duction and contained 50 mM HEPES, pH 7.5, and 1 mg/
ml lysozyme, E-64 protease inhibitor mix, and 10 units
Benzonase (EMD Biosciences/Novagen). The suspended
cells were sonicated using a Misonix 3000 sonicator
(Misonix, Farmingdale NY) using 10 s sonication pulses
for a total of 4 min with 30 s rest intervals between pulses.
Protein production analysis by denaturing
electrophoresis
Samples for total protein production analysis were pre-
pared for LabChip90 capillary electrophoresis (Caliper
Life Sciences, Hopkinton, MA) as recommended by the
manufacturer and were prepared for SDS-PAGE analysis
using Criterion SDS-PAGE polyacryalmide gels (4–20%
gradient Tris–HCl, 1.0 mm, 26 comb, BioRad, Richmond
CA) as previously reported [29]. The soluble protein
fraction was obtained by centrifuging the sample plates for
30 min at 2,200 9 g. Produced protein levels were deter-
mined by LabChip90 analysis and ﬂuorescence (AIA–
GFP). SDS- PAGE gels were analyzed using the Fotodyne
Imaging System (Fotodyne Inc, Hartland, WI) and Foto/
Analyst PC Image version 5.0 software.
Maxwell 16 puriﬁcation screening protocol
For small-scale protein puriﬁcation screening using the
Maxwell 16 system, E. coli B834-pRARE2 cells were
grown and genes expressed in isotopically enriched auto-
induction medium using 96-well growth blocks. The
growth was continued for 24 h until the culture had
reached saturation, and then the culture was harvested by
centrifugation (2,500 rpm for 2 min). The initial auto-
induction growth medium was removed, and the cells were
re-suspended by vortexing with 50 mM HEPES, pH 7.5,
containing a protease inhibitor cocktail [30] to give an
OD600 of 20 in 1 ml.
The vendor’s protocol and instructions were followed
for protein puriﬁcation. First, the Maxwell 16 protein
puriﬁcation cartridges were placed into the preparation
rack. The cartridge seals were removed, and one plunger
was placed into well #7 of each cartridge. An elution tube
was placed for each protein sample into the front of the
platform, and 300 ll of elution buffer was added to each
Table 1 Alternating coding and non-coding strand PCR primers used for construction of an optimized GFP gene
Primer Length Nucleotide sequence
a
1 90 CCCCCGGGGGCCCATATGTCCAAAGGTGAAGAACTGTTCACCGGTGT
TGTTCCGATCCTGGTTGAACTGGACGGTGACGTTAACGGTCAC
29 5 CTGCCACTGCAATTGCCAGTGTTTAAGAGGCAAAGGCCACTTCCAC
TTCCACTGCGATGGATGCCATTTGACTGGGACTTTAAGTAGACGTGGTG
39 4 CCTGAAATTCATCTGCACCACCGGTAAACTGCCGGTTCCGTGGCCG
ACCCTGGTTACCACCCTGACCTACGGTGTTCAGTGCTTCTCCCGTTAC
49 5 CAAGTCACGAAGAGGGCAATGGGCCTGGTGTACTTTGTCGT
GCTGAAGAAGTTTAGGCGATACGGCCTTCCAATGCAAGTCCTTGCATGGTAGAG
59 4 CGTTCAGGAACGTACCATCTCCTTCAAAGACGACGGTAACTACAAAACCCG
TGCTGAAGTTAAATTCGAAGGTGACACCCTGGTTAACCGTATC
69 4 CTGTGGGACCAATTGGCATAGCTTGACTTTCCATAGCTGAAGTTTC
TTCTGCCATTGTAGGACCCAGTGTTTGACCTTATGTTGATGTTGAGGG
79 2 GGAATACAACTACAACTCCCACAACGTTTACATCACCGCTGAC
AAACAGAAAAACGGTATCAAAGCTAACTTCAAAATCCGTCACAACATCG
89 4 GTTTTAGGCAGTGTTGTAGCTTCTGCCAAGGCAAGTCGACCGACTGGTGATGG
TCGTCTTGTGGGGCTAGCCACTGCCAGGCCAAGACGACGGC
99 4 GACGGTCCGGTTCTGCTGCCGGACAACCACTACCTGTCCACCCAGTCCGC
TCTGTCCAAAGACCCGAACGAAAAACGTGACCACATGGTTCTGC
10 90 GCACTGGTGTACCAAGACGACCTTAAGCAATGGCGACGACCATAGTGGGTGC
CATACCTGCTTGACATGTTTATTCGAACCTAGGGCCCC
a The underlined DNA sequences are the overlapping complementary annealing segments used to assemble the synthetic codon optimized GFP
gene. Primers numbered 1 (containing an NdeI site in bold) and 10 (with a Bam HI site in bold) are the ﬂanking oligonucleotides at the beginning
and end of the gene, respectively
156 R. O. Frederick et al.
123elution tube. Aliquots of the re-suspended cells were
transferred into well #1 of the Maxwell 16 puriﬁcation
cartridge, which also contained 109 Promega chemical
lysis buffer, and the puriﬁcation protocol was started. The
Maxwell 16 system required 45 min to complete the
puriﬁcation run. The ﬁnal puriﬁed proteins were removed
from the elution cuvettes and analyzed by denaturing SDS-
PAGE using either BioRad Criterion SDS-PAGE gels (4–
20% gradient Tris–HCl) or the Caliper LC90 system.
Puriﬁcation of Tcl-1 for NMR studies
A 50 ml (meso-scale) overnight culture (OD600 equal 10)
expressing Tcl-1 was harvested by centrifugation, and
re-suspended in *10 ml of 50 mM HEPES pH 7.5, with
protease inhibitor cocktail [30], 10 units of Benzonase
(EMD Biosciences/Novagen) to hydrolyze nucleic acids,
and 1 mg/ml of lysozyme to reduce the viscosity of the
lysate. The cell suspension was sonicated using a Sonic
Dismembrator 550 (Fisher Scientiﬁc) programmed to run
10 s sonication pulses for a total of 5 min (with 20 s rest
stops). Aliquots of the unclariﬁed cell lysate (1 ml) were
applied to well #1 of each lane of the Maxwell 16 cartridge,
which also contained the chemical lysis buffer. The Max-
well 16 protocol for His-tagged proteins was run, and the
puriﬁed His8-tagged protein samples from each lane were
pooled. The ﬁnal puriﬁed protein was exchanged into NMR
screening buffer (10 mM KHPO4, 50 mM KCl, 0.2%
NaN3, pH 7.0) and concentrated to a ﬁnal volume of 0.5 ml
Table 2 Structural genomics target proteins investigated
Lane
a Protein
b Mol. wt. (Da) pI Original pipeline
c Puriﬁcation screen
d Better prediction
e
Score Decision lg/ml Decision
A1 Homo sapiens MGC:16774 51,892.0 6.9 MMH Purify 883 Purify
A2 Homo sapiens MGC:120678 54,803.5 9.5 HHM Purify 0 Work stopped Yes
A3 Danio rerio MGC:103638 56,755.3 8.6 MMM Purify 273 Purify
A4 Homo sapiens MGC:120778 57,037.5 10.1 HMW Work stopped 93 Work stopped
A5 Xenopus laevis MGC53931 69,328.8 4.1 MMM Purify 286 Purify
A6 Danio rerio MGC:110031 70,033.3 9.4 MMM Purify 36 Work stopped Yes
A7 Danio rerio MGC:109975 74,013.6 6.6 WWW Work stopped 82 Work stopped
A8 Homo sapiens MGC:4153 78,593.1 7.7 WWW Work stopped 370 Purify No
f
A9 Xenopus laevis MGC78998 79,989.0 4.5 MMW Work stopped 491 Purify No
f
A10 Danio rerio MGC:110849 79,337.4 9.7 HHM Purify 45 Work stopped Yes
A11 Danio rerio MGC:113305 79,916.3 6.0 HMM Purify 283 Purify
A12 Danio rerio MGC:110805 84,575.6 4.8 HMM Purify 394 Purify
B1 Mus musculus MGC:5775 84,058.9 9.1 MMM Purify 10 Work stopped Yes
B2 Danio rerio MGC:113187 84,420.4 9.4 MMW Work stopped 11 Work stopped
B3 His8-MBP 44,000.0 5.5 nd Purify 361 Purify
B4 AIA–GFP 29,225.0 5.59 HHH Purify 859 Purify
a Lane corresponding to the electropherogram image of Fig. 2. Lanes A1–B2 are His8-MBP-target fusion proteins expressed from pVP56 that
cannot undergo in vivo cleavage. Lane B4 is His8-GFP expressed from pVP62 that can undergo in vivo cleavage
b Organism and mammalian gene collection identiﬁcation number or control protein described in the text
c The three-letter score represents an assessment of protein production (ﬁrst letter), solubility (second letter), and cleavage by TEV protease
(third letter) with H indicating high expression, high solubility or high efﬁciency of proteolysis, M indicating intermediate behavior for these
properties, and W indicating weak, unsuitable behavior. In our protocol ‘‘W’’ for any category is cause for ‘‘work stopped’’ on the target, while
‘‘H’’ or ‘‘M’’ scores advance a target to large-scale puriﬁcation. Use of this quantiﬁcation system has been published elsewhere [29]. In the
original pipeline scoring, 65% of the targets gave the exact same result, and the remaining 35% had variations, primarily in the scores for
solubility and proteolysis. The use of the in vivo cleavage vector pVP62 and puriﬁcation screening (Figs. 3 and 4) addresses the issue of
proteolysis as a part of the screening process by emphasizing the recovery of a puriﬁed protein rather than evaluation of intermediate steps
d The lg/ml reported for fusion proteins after automated puriﬁcation using the Maxwell 16 was from the Caliper LC90 analysis. A yield of
puriﬁed fusion protein greater than 100 lg/ml was used as the comparator for efﬁcacy of the puriﬁcation screening of His8-MBP fusion proteins
e Assessment of whether the Maxwell 16 puriﬁcation would lead to better predictive behavior in small-scale screening. Entries marked ‘‘Yes’’
correspond to targets that would not advance to puriﬁcation scale-up because they failed the automated Maxwell 16 puriﬁcation
f Targets marked ‘‘No’’ would have been advanced to puriﬁcation scale-up, but without an assessment of TEV proteolysis. Treatment of the
Maxwell-puriﬁed fusion protein with TEV protease gave weak cleavage, as observed in the original pipeline screen. This weak cleavage behavior
was reproduced in three additional samples produced in 2 l growths. The use of the in vivo cleavage vector pVP62 (Figs. 3 and 4) addresses the
issue of protease cleavage as part of the screening process
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123using Millipore Amicon ﬁltration devices. The total yield
of the [U-
15N]-Tcl-1 was *0.4 mg.
Puriﬁcation of GFP for NMR and X-ray studies
A 50 ml cell culture grown with auto-induction for 24 h
(OD600 equal to 10) with the appropriate isotopic label was
harvested by centrifugation, resuspended in 8–12 ml of
50 mM HEPES, pH 7.5, with protease inhibitors, benzon-
ase, and 1 mg/ml of lysozyme, and sonicated as above.
Aliquots (1 ml) of the unclariﬁed cell lysate were applied
to well #1 of eight lanes of the Maxwell 16 cartridge prior
to the puriﬁcation run. [U-
15N]-His8-GFP and [Se-Met]-
labeled His8-GFP puriﬁed in this manner were each
exchanged into the appropriate NMR [28] or X-ray [30]
screening buffer, and concentrated to ﬁnal volumes of
0.5 ml. The yield of the
15N labeled His8-GFP was 3.4 mg
from 50 ml of cell culture. The puriﬁed [Se-Met]-His8-
GFP was treated subsequently with TEV protease [46]t o
remove the His8 tag; the His8 tag and His8-tagged TEV
protease were removed by treatment with MagneHis par-
ticles; the buffer was exchanged, and the puriﬁed protein
was concentrated to a ﬁnal volume of 0.5 ml. The yield of
selenomethionine labeled AIA–GFP was 2.8 mg.
Protein characterization
Puriﬁed proteins were analyzed by denaturing electropho-
resis in the buffer described above. Concentrations were
determined using the Caliper LC90 software and the BCA
method (Pierce, Rockford IL). The masses of the puriﬁed
[U-
15N]- and [Se-Met]-labeled proteins were determined in
the University of Wisconsin Biotechnology Center by
electrospray ionization mass spectrometry using an
Applied Biosystems/MDS Sciex API 365 LC/MS/MS tri-
ple quadrupole mass spectrometer (Applied Biosystems,
Foster City, CA, USA). The labeling efﬁciency was cal-
culated from the experimentally determined and calculated
molecular weights of the protein. Protein identiﬁcation was
carried out by tryptic proteolysis and molecular weight
assignment of generated peptides using a Bruker BIFLEX
III MALDI-TOF spectrometer (Bruker Daltonics, Billerica,
MA, USA).
1H–
15N HSQC NMR
2D
1H–
15N HSQC spectra were acquired for [U-
15N]-
labeled Tcl-1 and [U-
15N]-labeled GFP at the National
Magnetic Resonance Facility at Madison (NMRFAM) on
600 and 750 MHz Bruker spectrometers equipped with
cryogenic
1H,
15N,
13C triple-resonance probes. The sam-
ple temperature was regulated at 35C. The NMR spectra
consisted of 1,024 and 100–110 complex data points,
respectively for
1H and
15N. For each increment, 128 scans
were used for [U-
15N]-labeled Tcl-1, and 16 scans were
used for [U-
15N]-labeled GFP.
Crystallization of AIA–GFP
AIA–GFP was screened initially using the UW192 screen.
From this screen, crystals were observed within 2 days
from ﬁve different conditions. One condition was opti-
mized for structure determination.
AIA–GFP crystals were grown by hanging drop vapor
diffusion. The crystals reached a size of
*0.1 9 0.1 9 1 mm rods in approximately 3 days at
25C in a mother liquor consisting of 100 mM HEPPS, pH
8.5, 80 mM CaCl2, and 15% PEG 4K. Hanging drops
consisted of 2.5 ll of protein solution and 2.5 ll of mother
liquor. Crystals were soaked in mother liquor containing
increasing amounts of glycerol to a ﬁnal concentration of
20% and ﬂash cooled in a stream of liquid nitrogen. X-ray
diffraction data were collected on a BrukerAXS PROTE-
UM R (BrukerAXS, Madison, WI) diffractometer at -
180C using CuKa radiation from a MicroStar (Bruke-
rAXS, Madison, WI) source with a rotating anode
generator operated at 44 kV and 45 mA. The X-ray data
were processed and scaled with PROTEUM 2 (Bruke-
rAXS, Madison, WI). The structure of GFP was solved by
molecular replacement using PDB 2g6e as the rotation
target with MOLREP from the CCP4 suite [47]. The model
was built with alternating cycles of model building and
reﬁnement with COOT [48] and REFMAC [49]. Coordi-
nates and structure factors were deposited in the Protein
Data Bank with accession number 2qu1.
Results
Met auxotrophy in E. coli B834
The strain E. coli B834 is frequently used for selenome-
thionine labeling [50]. It is a conditional methionine
auxotroph that can be complemented by the addition of
vitamin B12. The exact cause of the auxotrophy was not
known, but some believed that MetB was inactive [43],
while others thought that MetE was [45]. To better deﬁne
the origin of the auxotrophy, genomic DNA was isolated,
and the regions around the metE gene (GeneBank acces-
sion number DQ267751, encoding vitamin B12-
independent homocysteine transmethylase) and the metH
gene (GeneBank accession number DQ272318, encoding
158 R. O. Frederick et al.
123vitamin B12-dependent homocysteine transmethylase) were
sequenced.
Figure 2 shows the genome arrangement near to the
metE gene in E. coli K12 (capable of growth in the absence
of vitamin B12) and E. coli B834. DNA sequencing
revealed that E. coli B834 metE was truncated from 753
amino acids to an inactive 56-residue peptide by insertion
of a premature stop codon (TGA) and a DNA sequence
with homology to several genes previously identiﬁed from
the uropathogen E. coli CFT073 [52]. By contrast, the
sequence of the metH gene in E. coli B834 was intact and
matched (data not shown) the E. coli K12 gene [51]. Thus
methionine auxotrophy in E. coli B834 arises from dis-
ruption of the metE gene.
Proteins studied
Table 1 summarizes the primers used to synthesize the
modiﬁed GFP used in these studies. Other genes used in
this work were cloned as previously described [32], and
their properties are summarized in Tables 2 and 3. Results
from small-scale expression screening using a previously
described pipeline [29, 30] are included in Table 2, where
the score is an assessment of expression, solubility of the
fusion protein, and the ability of TEV protease to release
the target from the fusion protein. For example, human
MGC:16774 from lane A1 has a score of MMH for med-
ium protein production, medium solubility, and high
protease cleavage. By this assessment, this protein would
be suitable for puriﬁcation scale-up. In contrast, human
MGC:120778 from lane A4 has a score HMW for high
production, medium solubility, and weak protease cleav-
age. This protein would not be suitable for puriﬁcation
scale-up, because according to this protocol as any score of
W leads to ‘‘work stopped’’.
Maxwell 16 puriﬁcation screening
Figure 3 shows the results of small-scale production and
puriﬁcation of 14 different proteins from humans, frog,
mouse, and zebra ﬁsh as analyzed by Caliper LC90 elec-
trophoresis. The different proteins were produced in
factorial evolved auto-induction medium with selenome-
thionine [33]. The sizes of the fusion proteins ranged from
54 kDa to 86 kDa, and matched within ±20% of those
calculated from the gene sequences. The purity of the MBP
fusions ranged from 30% to 100% as estimated by the
capillary electrophoresis. The automated Caliper LC90
system also gave protein concentration estimates that were
in agreement with the manual BCA assays.
Of the 14 fusion proteins tested (A1–B2, Table 2 and
Fig. 3), seven were puriﬁed with yields exceeding 100 lg/
ml, six were puriﬁed with yields less than 100 lg/ml, and
one protein was not puriﬁed. Among the seven high yield
proteins, ﬁve also received a favorable assessment for
scale-up by the original scoring method; among the six low
yield proteins, three also received an unfavorable assess-
ment for scale-up by the original scoring method. Thus the
decision to scale-up the puriﬁcation or not was the same by
either method in eight of 14 cases.
Among the six proteins that were assessed differently by
the original method and the newer puriﬁcation screening,
Fig. 2 Conditional methionine auxotrophy in E. coli B834. (a)
Genome organization near to the metE gene in E. coli K12 [51].
(b) Genome organization near to the metE gene in E. coli B834. In
this organism, DNA sequencing revealed a large insert in the metE
gene, which caused the protein to be truncated to 56 amino acids (aa),
non-functional peptide
Table 3 Human embryonic stem cell proteins and others characterized by in vivo cleavage and puriﬁcation screening
Protein
a Annotation Database ID Mol. wt. (Da) Yield (lg/ml)
b
[U-
15N]-His8-Tcl-1 T-cell leukemia/lymphoma MGC:20335, 2260, 2170 13,459.6 7.5
CCNF Cyclin F MGC:20163 87,639.8 \1
C10orf96 Chromosome 10 open reading frame 96 MGC: 35062 31,035.3 Not detected
NPM2 Nucleophosmin/nucleoplasmin 2 MGC:78655 24,152.0 \1
[U-
15N]-His8-GFP Control protein, synthetic gene 26,842.4 68
SeMet-AIA–GFP Control protein, synthetic gene 29,226.0 172
a cDNA for the human proteins provided by Prof. James Thomson
b From Caliper LC90 analysis of the protein obtained from Maxwell 16 puriﬁcation
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123there were two outcomes. One outcome, exempliﬁed by
A2, A6, A10, and B1, were proteins that had a favorable
score by the original method, but that were not puriﬁed in
yield [100 lg/ml by the newer puriﬁcation screening
protocol. Use of puriﬁcation screening would eliminate
unnecessary scale-up effort for a class of proteins that
ultimately fail in puriﬁcation. The other outcome, exem-
pliﬁed by A8 and A9, was a successful puriﬁcation of a
large amount of protein when the work would have been
stopped by the original method. Since the results of Fig. 3
with A8 and A9 do not include a proteolysis step, the
original screen provided additional information suggesting
that these targets would ultimately fail in puriﬁcation
because they had an unsuitable W score for proteolysis.
Indeed, when A8 and A9 obtained from the Maxwell were
treated with TEV protease, neither target was successfully
liberated from the fusion protein.
In order to address this deﬁciency in the puriﬁcation
screening, we developed an in vivo cleavage expression
vector to couple with the Maxwell 16 puriﬁcation system.
The assembly of this vector and results of using this
combination for puriﬁcation screening of human embry-
onic stem cell proteins is described in the following
sections.
Puriﬁcation screening of human stem cell proteins
Table 3 identiﬁes the four human stem cell proteins studied
and Fig. 4 shows the results of Maxwell 16 puriﬁcation for
the human proteins and AIA–GFP that were expressed
from the in vivo cleavage plasmid pVP62K. As judged by
the appearance of a prominent protein band from the
in vivo proteolyzed MBP, the auto-induction process was
successfully executed for all ﬁve proteins. However, only
human embryonic stem cell T-cell lymphoma-1 (Tcl-1,
lane 7) and AIA–GFP (lane 11) were successfully puriﬁed
in large quantities. Two other stem cell proteins were
apparently puriﬁed in small quantities (C10orf96 and
NPM2, lanes 5 and 9, respectively), but not in sufﬁcient
amounts for scale-up.
Replicate Maxwell 16 puriﬁcation of Tcl-1
The number of replicate Maxwell 16 lanes required to
purify sufﬁcient [U-
15N]-His8-Tcl-1 protein for
1H–
15N
HSQC measurements was estimated on the basis of the
BCA quantiﬁcation of the single lane results (Fig. 4, lane
7). Figure 5 shows the results of the repetitive puriﬁcations
from a 50 ml meso-scale cell culture. Each well held the
cell lysate from the equivalent of *4 ml of cell culture.
The cell lysate was processed by a modiﬁcation of the
manufacturer’s protocol as described in Materials and
Methods. After the Maxwell 16 puriﬁcation, the individual
wells were pooled. The pooled sample was concentrated
and exchanged into a buffer suitable for NMR studies.
Fig. 3 Caliper LC90 analysis of His8-tagged proteins puriﬁed by
Maxwell 16. Lanes LA and LB are molecular weight markers. Lanes
A1–B2 are structural genomics target proteins (protein bands marked
with ovals) with molecular weight *50–75 kDa. They were
expressed in factorial evolved auto-induction medium containing
selenomethionine [33] as an N-terminal fusion with MBP from
pVP56K, a vector that does not give in vivo proteolysis of the fusion
protein. Lane B3 contains His8-MBP (protein band marked with
oval), while lane B4 (1.1 mg/ml) contains His8-GFP expressed from
pVP62 after in vivo cleavage from MBP. Lanes with a puriﬁed
expressed fusion protein with yield than 100 lg/ml are marked with a
star (also see Table 2 )
Fig. 4 Small-scale puriﬁcation screening of human embryonic stem
cell proteins. Human stem cell proteins were expressed in E. coli
B834 by auto-induction, liberated by in vivo proteolysis, and puriﬁed
by the Maxwell 16 puriﬁcation system. Table 2 provides further
information on these proteins. Lane 1, molecular weight markers.
Lanes 2 and 3, total cell lysate and eluted sample from puriﬁcation of
CCNF. No puriﬁed protein was detected. Lanes 4 and 5, C10orf96
was obtained in detectable amounts, but not sufﬁcient for scale-up,
along with two higher molecular weight contaminants. Lanes 6 and 7,
His8-Tcl-1 was expressed, proteolyzed, and successfully puriﬁed.
Lanes 8 and 9, NPM2 was expressed and proteolyzed, but only a
small amount of protein was puriﬁed. In addition, the puriﬁed protein
appeared to be partially degraded. Lanes 10 and 11, His8-GFP
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123These post-puriﬁcation handling steps took *1.5 h. In
total, *0.4 mg of pure [U-
15N]-His8-Tcl-1 protein was
obtained. The percentage incorporation of
15N in puriﬁed
His8-Tcl-1 was determined by electrospray ionization mass
spectrometry to be greater than 95%.
A similar scale-up of the initial expression results was
undertaken for AIA–GFP (Fig. 4, lane 11) with either
[U-
15N]- or [Se-Met]-labeling. The expressed AIA–GFP
had high ﬂuorescence, and could be easily observed by
visual inspection at all steps of the automated puriﬁcation.
The identity of puriﬁed AIA–GFP was conﬁrmed by tryptic
proteolysis and liquid chromatography/tandem mass spec-
trometry. The yield of [U-
15N]-His8-GFP was *3.4 mg.
This sample was pooled and concentrated, and further
exchanged into a buffer suitable for NMR studies (*2 h).
For X-ray crystallography, the His8-tag was removed by
treatment with TEV protease. The ﬁnal yield of puriﬁed
AIA–GFP was 2.8 mg, and a high level of selenomethio-
nine was incorporated into the puriﬁed AIA–GFP as
determined by electrospray ionization mass spectrometry.
NMR characterization
Figure 6a shows the 750 MHz
1H–
15N HSQC spectrum of
His8-Tcl-1. This spectrum was acquired in 9.5 h. The
HSQC spectrum of His8-Tcl-1 is characteristic of a folded
protein [28]. Including cross peaks from the Asn, Gln and
Trp sidechains and excluding the ﬂexible N-terminal His-
tag and TEV protease site, 102 out of the possible 117 cross
peaks for the native protein were present. The favorable
peak count and the observed chemical shift dispersion
indicate that His8-Tcl-1 is amenable for NMR structural
analysis [28].
Figure 6b shows the 600 MHz
1H–
15N HSQC NMR
spectrum of His8-GFP recorded at 25C. This spectrum
was acquired in 1 h. For this GFP, a total of about 219
cross peaks out of a possible 253 cross peaks (including
amino acid chain amides) were present. The broader NMR
line widths due to the larger size of GFP (238 aa,
*27,000 Da) account for some the difference between the
numbers of expected and observed cross peaks. Neverthe-
less, the chemical shifts are well dispersed, suggesting that
the Maxwell-puriﬁed protein was well structured in solu-
tion and thus acceptable for further structural studies.
X-ray structure of AIA–GFP
The AIA–GFP was screened for crystallization using the
UW192 crystallization screen. As AIA–GFP contained
Fig. 5 Replicate Maxwell 16 puriﬁcation of human embryonic stem
T-cell lymphoma-1 protein. Lane 1, molecular weight markers. Lanes
2–12, replicate puriﬁcations of His8-Tcl-1. Lane 13, His8-MBP-
At2g34690.1, an Arabidopsis thaliana protein expression control
Fig. 6
1H–
15N HSQC NMR spectra of Maxwell-puriﬁed proteins
Tcl-1 and GFP. (a) 750 MHz spectrum of His8-Tcl-1 obtained at
35C (1.75 mg in 250 ll of 10 mM KHPO4, pH 7, containing 50 mM
KCl). The total NMR time required to obtain this spectrum was 9.5 h.
(b) 600 MHz spectrum of His8-GFP obtained at 35C (5.6 mg in
250 ll of 10 mM KHPO4, pH 7, containing 50 mM KCl). The total
NMR time required to obtain this spectrum was 1 h
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123several surface mutations, and in addition, the N-terminal
AIA sequence derived from the Flexi Vector cloning pro-
tocol [32], several unique crystallization conditions were
identiﬁed by the crystallization screening. Table 4 shows
the ﬁve conditions that gave crystals within 2 days.
Condition 4 was selected for optimization, and the
resulting crystals diffracted well. The structure of GFP was
solved by molecular replacement at a resolution of 1.7 A ˚.
Table 5 shows data collection statistics and results of the
structure determination, while Fig. 7 shows the structure of
AIA–GFP. Interpretable electron density was observed
from all residues of the protein. Consistent with this
observation, the chromophore consisting of cross-linked
residues T65, Y66, and G67 was clearly present in the
reﬁned structure. In total, this effort used 2.8 mg of the
protein provided from eight lanes of the Maxwell 16
puriﬁcation system.
Discussion
Figure 8 shows a schematic workﬂow for puriﬁcation-
based screening of expressed proteins. We have applied
this approach to eukaryotic proteins, including those from
human embryonic stem cells. The advantages of the
approach include the small quantity of cell culture
required, the speed in going from cells to puriﬁed protein,
the relatively low cost of the procedure, the ability to scale
up to automated, multiple-lane puriﬁcations, and the pro-
tein yields, which are sufﬁcient to support characterization
of the protein product.
Puriﬁcation screening
Protein production pipelines have numerous points of
attrition that limit the number of proteins available for
structural analysis. This attrition adds signiﬁcant expense
to the overall process, particularly when multiple handling
steps and larger volumes are typically required to obtain
decisions. Thus the use of small- or micro-scale protein
screening methods has considerable appeal [22, 24].
The focus of this work has been on eukaryotic proteins,
which are generally found to be more difﬁcult to express
and purify than prokaryotic proteins. Small-scale
production screening efforts have predicted the outcome of
downstream large-scale protein production with up to 80%
efﬁciency [26]. However, these previous efforts did not
Table 4 Summary of
crystallization conditions
observed for AIA–GFP
a Conditions present in the
UW192 crystallization screen
used at UW Center for
Eukaroytic Structural Genomics
Condition
a Precipitant (w/v) Buffer Salt
1 24% MEPEG 5K 0.1 M MES, pH 6.0 160 mM CaCl2
2 16% MEPEG 5K 0.1 M BTP, pH 7.0 200 mM glycine
3 28% MEPEG 2K 0.1 M HEPES, pH 7.5 100 mM CaCl2
4 20% PEG 4K 0.1 M HEPPS, pH 8.5 80 mM CaCl2
5 60% MPD 0.1 M MES, pH 6.0 None
Table 5 Summary of data collection, crystal structure, and reﬁne-
ment statistics for AIA–GFP
Data collection
a
Space group P212121
Cell dimensions
a, b, c (A ˚) 51.46, 61.99, 70.02
a, b, c () 90, 90, 90
Resolution (A ˚)
b 46.42–1.70 (1.74–1.70)
No. reﬂections 23752
Rmerge (%)
c 15.7 (36.6)
(I/rI)
d 28.27 (2.93)
Completeness (%) 98.98 (97.32)
Redundancy 29.45 (5.42)
Reﬁnement
e,f
Resolution (A ˚) 46.42–1.70 (1.74–1.70)
No. reﬂections 23752 (1276)
Rwork/Rfree 0.168/0.220 (0.246/0.323)
No. atoms
Protein 1915
g
Water 377
Mean B-value (overall) 12.34
Ramachandran analysis
Most favored regions 92.4
Additional allowed regions 7.6
RMS deviations
Bond lengths (A ˚) 0.012
Bond angles () 1.548
a Data collected at University of Wisconsin Center for Eukaryotic
Structural Genomics. Coordinates and structure factors were depos-
ited in the Protein Data Bank with accession number 2qu1
b Numbers in parentheses indicate the highest resolution shell of 20
c Rmerge = R |I -\I[|/R I, where I is the observed intensity and
\I[is the average intensity obtained from multiple measurements
d The root-mean-squared value of the intensity measurements divided
by their estimated standard deviation
e Rwork = R ||F0 | - | Fc ||/R | F0 |, where | F0 | is the observed
structure factor amplitude and | Fc | is the calculated structure factor
amplitude
f Rfree = R-factor based on 5.1% of the data excluded from
reﬁnement
g Number of non-hydrogen protein atoms included in reﬁnement
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123effectively address either the variability in proteolysis of
fusion proteins that are often used to express eukaryotic
proteins in E. coli or the behavior of the liberated targets
after proteolysis. By adopting this screening approach, the
decision to scale-up protein production can be based on the
ability to express, proteolyze, and purify the protein, and as
indicated here, this decision can be extended to the ability
to include other information such as acceptable
1H–
15N
HSQC spectra or evidence of crystallization.
Table 2 contains information on another troublesome set
of eukaryotic proteins, those with pI *8 or greater (A2,
A3, A4, A10, B1, B2). Puriﬁcation screening would
provide important insight into the behavior of these
proteins, which often perform well as fusion proteins in
total production and solubility properties, but which often
fail in proteolysis or stability after proteolysis (*70%,
unpublished results). Thus, although the original pipeline
screening suggested A2, A6, A10, and B1 should have
been advanced to puriﬁcation, each of these targets failed
to achieve the desired threshold from the Maxwell puriﬁ-
cation for puriﬁed fusion protein and thus deserved a work
stopped assignment. In contrast, the high pI protein A3 was
puriﬁed in high yield as a fusion protein from the Maxwell
and subsequently was released by TEV protease treatment
(as in the original pipeline scoring), supporting the decision
that this protein should be continued along the scale-up
process. Further consideration of the results of these targets
will be included in a broader study of the effect of the
N-terminal AIA tag on protein puriﬁcation and structure
determination statistics, which will be reported elsewhere.
Scalability
Scalability requires similar protein production behavior in
small-scale screening, large-scale protein production, and,
ultimately, protein puriﬁcation. For proteins A8 and A9,
the original small-scale screening reported these proteins
were unsuitable because of a failure in TEV proteolysis,
and this result was also determined after Maxwell puriﬁ-
cation. Among the four human embryonic stem cell
proteins investigated, Tcl-1 was highly expressed by auto-
induction, underwent efﬁcient in vivo proteolysis from
MBP, and was successfully puriﬁed with an estimated
volumetric productivity of 7.5 lg/ml. Two other stem cell
proteins (C10orf96 and NPM2), were also puriﬁed, but
their yields were not sufﬁcient to indicate feasibility of the
scale-up as a structural target. Nevertheless, the method
yielded enough puriﬁed protein that some functional
studies or other analyses could be undertaken. By coupling
in vivo cleavage with automated puriﬁcation, failure to
proteolyze the His8-target from the fusion protein and
cryptic insolubility of the His8-target after proteolysis are
Fig. 7 X-ray structure of AIA–GFP. The chromophore is shown as
green cylinders representing bonded atoms
Fig. 8 Schematic of a puriﬁcation screening protocol. Steps from
obtaining a sequence-veriﬁed target in auto-cleavage vector pVP62K
to identiﬁcation of puriﬁed proteins. The transformed expression host
is grown in auto-induction medium. Cells from production trials are
loaded into the Maxwell 16 instrument for automated puriﬁcation, and
puriﬁed proteins are detected by Caliper LC90 capillary electropho-
resis. Successful puriﬁcation of a protein from auto-cleavage
expression with yield exceeding 50 lg/ml of culture medium
indicates feasibility of scale-up efforts
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123signaled by failure in automated puriﬁcation. Since both of
these results are diagnostic of likely failures in large-scale
puriﬁcation, the puriﬁcation screening approach gave
valuable insight into the behavior of the human stem cell
protein CCNF and the others before any signiﬁcant scale-
up efforts were undertaken.
We demonstrated how the amount of His8-target suc-
cessfullypuriﬁed from asingleMaxwell 16lane can beused
to determine the scale-up factor required to prepare samples
for screening either by
1H–
15N NMR for folding status
(*700 lg of a 25 kDa or less protein set as the deliverable)
or by microﬂuidic screening for crystallization (*10 lgo f
protein set as the deliverable). This scaling approach was
demonstrated for both Tcl-1 and AIA–GFP. Decreasing the
amount of protein required for initial structural screening
through the use of small NMR tubes, cryoprobes, and by nL
liquid handling effectively complements the ability to pro-
duce moderate amounts of protein in the cost-effective
manner described here. Automated methods for removal of
the His8-tag during the Maxwell 16 run would also be
desirable, and these investigations are in progress.
Time
CESG starts all expression work on eukaryotic proteins
with sequence veriﬁed clones [32, 53]. Uncertainties in
gene models and errors from primer synthesis are addres-
sed by this effort, while immediate sequence veriﬁcation of
a cloned gene also supports reliable transfer into other
expression vectors. Expression plasmids transformed into
E. coli B834 can be available for puriﬁcation screening
studies after 24 h, and growth from single colony trans-
formants can be completed in 48 h using our auto-
induction approach (24 h of growth in non-inducing med-
ium followed by 24 h of growth in inducing medium).
Auto-induced cultures can be immediately loaded onto the
Maxwell 16 apparatus, with parallel processing of 16
samples in 45 min. Thus a complete 96-well plate of dif-
ferent targets (or variants of the same target) could be
puriﬁed and analyzed for protein expression by the auto-
mated capillary electrophoresis in less than 7 h. In the
work ﬂow of Fig. 8, the best performing targets, provi-
sionally deﬁned as those obtained from in vivo cleavage
and automated puriﬁcation in yield of 50 lg/ml or greater,
can be identiﬁed in about 4 days, with most of the elapsed
time allotted to overnight culture growths or automated
protein puriﬁcation.
Cost
Auto-induction media are chemically deﬁned and assem-
bled from inexpensive components. Furthermore, the cost
of labeled amino acids (
15N or Se-Met) is minimal for the
initial screening due to the small cell culture volume
required. For the example shown in Fig. 4, the cost for all
reagents for the auto-induction and automated puriﬁcation
of the
15N-labeled sample was less than $50. The simple
instrumentation required for the auto-induction and the
Maxwell 16 puriﬁcation may allow wide access to this
approach, and the minimal hands-on effort required to
complete the analysis through to puriﬁed protein is another
considerable operational advantage.
Capillary electrophoresis has several advantages relative
to slab gel electrophoresis. Although the instrument is more
expensive than a standard power supply, electrophoresis
equipment, and gel documentation system, the average
price per sample analysis (*$0.67 per lane of analysis)
using the LC90 chip is less than pre-cast polyacrylamide
gels (*$1.17 per lane of analysis). Other advantages of
capillary electrophoresis include automated operation,
rapid processing time, digital information capture, and
quantitative analysis of electropherograms. This work
shows that the quantitative analysis of protein yield from a
small-scale expression can be used as a predictive tool for
scale-up feasibility.
Other applications of this approach
The automated protein puriﬁcation process described here
has other potential uses. This process can facilitate evalu-
ation of different vector designs and arrays of different
expression hosts. For functional studies, banks of site-
directed or randomly mutated proteins can be prepared and
puriﬁed in amounts sufﬁcient for catalytic screening. This
may facilitate protein engineering for new traits that can be
assayed such as changes in catalytic activity, thermal sta-
bility, or other desirable properties. In many cases, the
amounts of protein recovered by the automated puriﬁcation
(Tables 2 and 3) should be adequate to initiate these
functional studies. Surface entropy reduction analysis
could also be facilitated through an effective sorting of
protein variants that maintain sufﬁcient stability to be
puriﬁed. The delivery of small quantities of puriﬁed pro-
teins for examination by micro-crystallization techniques
or NMR analysis before signiﬁcant effort is placed into
purifying large quantities also has demonstrable
advantages.
For eukaryotic proteins, domain engineering is an
important experimental focus. It is clear that multiple
changes at the N- and C-terminus may be required to
identify the best performing variant. Through the use of
puriﬁcation screening, it is efﬁcient to express, purify, and
examine engineered domains for improved solubility
properties as part of the experimental process.
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